CN114746430B - 治疗线粒体异常疾病的伐替苯醌的醌-、氢醌-和萘醌-类似物 - Google Patents

治疗线粒体异常疾病的伐替苯醌的醌-、氢醌-和萘醌-类似物

Info

Publication number
CN114746430B
CN114746430B CN202080084283.6A CN202080084283A CN114746430B CN 114746430 B CN114746430 B CN 114746430B CN 202080084283 A CN202080084283 A CN 202080084283A CN 114746430 B CN114746430 B CN 114746430B
Authority
CN
China
Prior art keywords
compound
och
independently
ocf
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080084283.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN114746430A (zh
Inventor
D·基夫
郑国柱
P·阿森詹斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kant Biomedical Co ltd
Original Assignee
Kant Biomedical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kant Biomedical Co ltd filed Critical Kant Biomedical Co ltd
Priority to CN202610035916.3A priority Critical patent/CN121949079A/zh
Publication of CN114746430A publication Critical patent/CN114746430A/zh
Application granted granted Critical
Publication of CN114746430B publication Critical patent/CN114746430B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/10—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having one or more double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/18—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with unsaturation outside the aromatic ring
    • C07C39/19—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with unsaturation outside the aromatic ring containing carbon-to-carbon double bonds but no carbon-to-carbon triple bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/82—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
    • C07C49/835—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups having unsaturation outside an aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C07C50/26—Quinones containing groups having oxygen atoms singly bound to carbon atoms
    • C07C50/28—Quinones containing groups having oxygen atoms singly bound to carbon atoms with monocyclic quinoid structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D305/06—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
CN202080084283.6A 2019-10-04 2020-10-02 治疗线粒体异常疾病的伐替苯醌的醌-、氢醌-和萘醌-类似物 Active CN114746430B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202610035916.3A CN121949079A (zh) 2019-10-04 2020-10-02 治疗线粒体异常疾病的伐替苯醌的醌、氢醌和萘醌类似物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962911069P 2019-10-04 2019-10-04
US62/911,069 2019-10-04
US202062991525P 2020-03-18 2020-03-18
US62/991,525 2020-03-18
PCT/US2020/054107 WO2021067836A1 (en) 2019-10-04 2020-10-02 Chinone-, hydrochinome- and naphthochinone-analogues of vatiquione for treatment of mitochondrial disorder diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202610035916.3A Division CN121949079A (zh) 2019-10-04 2020-10-02 治疗线粒体异常疾病的伐替苯醌的醌、氢醌和萘醌类似物

Publications (2)

Publication Number Publication Date
CN114746430A CN114746430A (zh) 2022-07-12
CN114746430B true CN114746430B (zh) 2026-01-30

Family

ID=72964859

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080084283.6A Active CN114746430B (zh) 2019-10-04 2020-10-02 治疗线粒体异常疾病的伐替苯醌的醌-、氢醌-和萘醌-类似物
CN202610035916.3A Pending CN121949079A (zh) 2019-10-04 2020-10-02 治疗线粒体异常疾病的伐替苯醌的醌、氢醌和萘醌类似物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202610035916.3A Pending CN121949079A (zh) 2019-10-04 2020-10-02 治疗线粒体异常疾病的伐替苯醌的醌、氢醌和萘醌类似物

Country Status (9)

Country Link
US (4) US11584728B2 (cg-RX-API-DMAC10.html)
EP (1) EP4038076A1 (cg-RX-API-DMAC10.html)
JP (2) JP2022551270A (cg-RX-API-DMAC10.html)
KR (1) KR20220078644A (cg-RX-API-DMAC10.html)
CN (2) CN114746430B (cg-RX-API-DMAC10.html)
AU (2) AU2020358970C1 (cg-RX-API-DMAC10.html)
CA (1) CA3156499A1 (cg-RX-API-DMAC10.html)
IL (2) IL291898B1 (cg-RX-API-DMAC10.html)
WO (1) WO2021067836A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL291898B1 (en) * 2019-10-04 2026-06-01 Stealth Biotherapeutics Inc Quinone-, hydroquinone-, and naphthoquinone- analogs of quinone for the treatment of mitochondrial disorders
AU2022291142A1 (en) * 2021-06-10 2023-12-21 Stealth Biotherapeutics Inc. Compounds, compositions and methods for the prevention and/or treatment of various mitochondrial diseases or disorders, including friedreich's ataxia
US11541116B1 (en) 2022-01-07 2023-01-03 Kojin Therapeutics, Inc. Methods and compositions for inducing ferroptosis in vivo
AU2024300048A1 (en) * 2023-07-21 2026-01-22 Stealth Biotherapeutics Inc. Methods, compositions and uses related to the treatment and prevention of leigh's syndrome
AU2024377199A1 (en) * 2023-11-09 2026-05-21 Stealth Biotherapeutics Inc. Cyclo-hexa-2,5-diene-1,4-diones for use in the treatment of cardiomyopathy
WO2025231245A1 (en) * 2024-05-02 2025-11-06 Stealth Biotherapeutics Inc. Use of substituted 1,4 benzoquinones to treat alpha-synucleinopathies
WO2026020091A1 (en) * 2024-07-19 2026-01-22 Stealth Biotherapeutics Inc. Methods, compounds, compositions, formulations and uses for addressing mitochondrial disease resulting from nuclear dna mutations
WO2026050137A1 (en) * 2024-08-26 2026-03-05 Stealth Biotherapeutics Inc. A combination therapy for the treatment of friedreich's ataxia

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2332534A1 (en) * 2006-02-22 2011-06-15 Edison Pharmaceuticals, Inc. Phenol and benzoquinone derivatives for use in the treatment of mitochondrial diseases and modulation of energy biomarkers
WO2012022467A2 (en) * 2010-08-16 2012-02-23 Santhera Pharmaceuticals (Schweiz) Ag Novel benzoquinone derivatives and use thereof as modulators of mitochondrial function
WO2017087795A1 (en) * 2015-11-19 2017-05-26 Concert Pharmaceuticals, Inc. Deuterated epi-743

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JP3507486B2 (ja) 1991-03-15 2004-03-15 アムジエン・インコーポレーテツド 顆粒球コロニー刺激因子の肺内投与
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
CA2272971C (en) 1998-10-29 2008-01-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Quinone derivatives for treating or preventing diseases associated with iron overload
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
WO2005033092A1 (en) 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. Chroman derivatives
EA035619B1 (ru) * 2005-06-01 2020-07-16 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Композиции для использования в способе лечения митохондриальных нарушений
JP2009508867A (ja) 2005-09-15 2009-03-05 エジソン ファーマシューティカルズ, インコーポレイテッド ミトコンドリア病および関連した様態の治療ならびにエネルギーバイオマーカーの調節のための酸化還元活性治療剤のテイル改変体
EP1986636B1 (en) 2006-02-22 2013-04-24 Edison Pharmaceuticals, Inc. Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases
WO2009111576A2 (en) 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc. 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
EP2303824B1 (en) 2008-06-25 2015-03-25 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
EP2344142B1 (en) 2008-09-10 2024-06-26 PTC Therapeutics, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
WO2010051277A1 (en) 2008-10-28 2010-05-06 Edison Pharmaceuticals, Inc. Process for the production of alpha-tocotrienol and derivatives
EP2246048A1 (en) 2009-04-30 2010-11-03 Santhera Pharmaceuticals (Schweiz) AG Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone for the treatment of primary progressive multiple sclerosis
NO2470168T3 (cg-RX-API-DMAC10.html) 2009-08-26 2018-06-30
US20130345312A1 (en) 2010-08-06 2013-12-26 Orion D. Jankowski Treatment of mitochondrial diseases with naphthoquinones
HRP20161407T1 (hr) 2010-08-16 2016-12-02 Santhera Pharmaceuticals (Schweiz) Ag Derivati benzokinona za liječenje mitohondrijskih bolesti oka
WO2012068552A1 (en) 2010-11-19 2012-05-24 Edison Pharmaceuticals, Inc. Methods for improving blood glucose control
WO2012170773A1 (en) 2011-06-08 2012-12-13 Edison Pharmaceuticals, Inc. Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones
KR102137450B1 (ko) * 2012-07-12 2020-07-27 콘드리온 아이피 비.브이. 미토콘드리아 질환을 치료하기 위한 크로마닐 유도체
CA2883879A1 (en) 2012-09-07 2014-03-13 Edison Pharmaceuticals, Inc. Quinone derivatives for use in the modulation of redox status of individuals
JP6367211B2 (ja) 2012-11-16 2018-08-01 ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ リソソーム蓄積症の改善物質としてのトコフェロール誘導体およびトコフェリルキノン誘導体
JP2016515526A (ja) * 2013-03-15 2016-05-30 エジソン ファーマシューティカルズ, インコーポレイテッド 酸化ストレス障害の処置のためのアルキル−ヘテロアリール置換されたキノン誘導体
WO2015183963A2 (en) 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including redox-active parabenzoquinones and uses thereof
EP3389646A1 (en) 2015-12-17 2018-10-24 BioElectron Technology Corporation Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
CA3011293A1 (en) 2016-01-12 2017-07-20 Ptc Therapeutics, Inc. Tocopherol and tocotrienol quinone derivatives for increasing thiosulfate levels or decreasing hydrogen sulfide levels
WO2018191732A1 (en) 2017-04-14 2018-10-18 Bioelectron Technology Corporation Methods and compositions for treatment of inflammation and oxidative stress
JP7266304B2 (ja) 2017-04-21 2023-04-28 ユニヴァーシティー オブ タスマニア 治療化合物および方法
IL305687B2 (en) 2017-12-15 2024-12-01 Stealth Biotherapeutics Inc Mitochondria-targeting peptides
IL291898B1 (en) * 2019-10-04 2026-06-01 Stealth Biotherapeutics Inc Quinone-, hydroquinone-, and naphthoquinone- analogs of quinone for the treatment of mitochondrial disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2332534A1 (en) * 2006-02-22 2011-06-15 Edison Pharmaceuticals, Inc. Phenol and benzoquinone derivatives for use in the treatment of mitochondrial diseases and modulation of energy biomarkers
WO2012022467A2 (en) * 2010-08-16 2012-02-23 Santhera Pharmaceuticals (Schweiz) Ag Novel benzoquinone derivatives and use thereof as modulators of mitochondrial function
WO2017087795A1 (en) * 2015-11-19 2017-05-26 Concert Pharmaceuticals, Inc. Deuterated epi-743

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Asymmetric syntheses of daedalin A and quercinol and their tyrosinase inhibitory activity;Hattori Y et al.;Bioorganic and Medicinal Chemistry Letters;20091211;第20卷(第3期);第1063-1064页 *
Construction of Bridged-Ring-Fused Naphthalenone Derivatives Through an Unexpected Zn(OTf)2-Catalyzed Cascade Transformation;Chandraiah Lagishetti et al.;Organic Letters;20190620;第21卷(第13期);第5301-5304页 *
Synthesis of the Amido Hydroquinone Core and the C10-C15 Fragment.Synlett.2012,第19卷第2845-2849页. *
Zhao, GL et al..Toward a Total Synthesis of Divergolide A *

Also Published As

Publication number Publication date
WO2021067836A1 (en) 2021-04-08
AU2020358970B2 (en) 2026-02-05
US11584728B2 (en) 2023-02-21
KR20220078644A (ko) 2022-06-10
AU2020358970C1 (en) 2026-08-06
US20210206736A1 (en) 2021-07-08
IL328635A (en) 2026-07-01
CA3156499A1 (en) 2021-04-08
CN114746430A (zh) 2022-07-12
CN121949079A (zh) 2026-05-01
JP2025164962A (ja) 2025-10-31
JP2022551270A (ja) 2022-12-08
US20240368098A1 (en) 2024-11-07
IL291898B1 (en) 2026-06-01
US20230303506A1 (en) 2023-09-28
EP4038076A1 (en) 2022-08-10
AU2026203365A1 (en) 2026-07-23
US12049455B2 (en) 2024-07-30
US20240400529A1 (en) 2024-12-05
IL291898A (en) 2022-06-01
AU2020358970A1 (en) 2022-04-14

Similar Documents

Publication Publication Date Title
CN121949079A (zh) 治疗线粒体异常疾病的伐替苯醌的醌、氢醌和萘醌类似物
CN115996916B (zh) 用于预防和/或治疗包括弗里德赖希共济失调的线粒体疾病的组合物和方法
CA3222132A1 (en) Compounds, compositions and methods for the prevention and/or treatment of various mitochondrial diseases or disorders, including friedreich's ataxia
JP2021523934A (ja) ミトコンドリア脱共役剤として有用なアミノピラジンおよび関連化合物
EP2814479B1 (en) Methods of treating amyotrophic lateral sclerosis
CN114728920B (zh) 一种沃替西汀前药及其应用
WO2023272571A1 (zh) 2,3-环氧丁二酰衍生物的医药用途
WO2024239762A1 (zh) 磷酸二酯酶4抑制剂、其药物组合物及其应用
WO2015154716A1 (zh) 菲罗啉膦酸类衍生物及其制备方法和应用
CN113387909B (zh) 2,3-环氧丁二酰衍生物的医药用途
EP3641756A1 (en) Tricyclic compounds as cyp1 inhibitors
CN118382435A (zh) 12/15-脂氧合酶抑制剂
HK40088188B (en) Compositions and methods for preventing and/or treating mitochondrial diseases, including friedreich's ataxia
JP2024520758A (ja) Ttbk1の阻害剤
HK40088188A (en) Compositions and methods for preventing and/or treating mitochondrial diseases, including friedreich's ataxia
IT202400002560A1 (it) Inibitori della proteina rock per uso nel trattamento della fibrosi polmonare
WO2020028552A1 (en) Methods of activating microglial cells

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant